Profile data is unavailable for this security.
About the company
Zhejiang Starry Pharmaceutical Co Ltd is a China-based company mainly engaged in the research and development, production and sales of pharmaceutical specialty raw materials. The Company's business includes the production and sales of intermediates, APIs and preparations of iodine contrast agent series products such as iohexol, iopamidol, iodixanol, iomeprol, ioversol and iopromide. The Company's main products are non-ionic iodine contrast agent series drugs, levofloxacin series products, levofloxacin APIs and intermediates.
- Revenue in CNY (TTM)2.27bn
- Net income in CNY46.95m
- Incorporated1997
- Employees1.85k
- LocationZhejiang Starry Pharmaceutical Co LtdXianjuTAIZHOU 317306ChinaCHN
- Phone+86 57 687718605
- Fax+86 57 687718686
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hainan Huluwa Pharmaceutical Grop Co Ltd | 1.81bn | 94.97m | 3.75bn | 2.47k | 39.52 | 3.26 | -- | 2.08 | 0.2374 | 0.2374 | 4.52 | 2.87 | 0.6721 | 2.88 | 3.81 | 732,708.90 | 3.80 | 5.81 | 6.29 | 9.78 | 50.33 | 58.01 | 5.66 | 7.03 | 0.8245 | 7.04 | 0.5246 | 21.74 | 25.75 | 14.13 | 24.29 | 1.16 | 46.37 | -- |
| Sinotherapeutics Inc | 368.86m | 76.25m | 3.75bn | 260.00 | 49.23 | 3.13 | -- | 10.18 | 0.1682 | 0.1682 | 0.8137 | 2.65 | 0.275 | 3.08 | 5.83 | 1,418,710.00 | 5.69 | -- | 6.09 | -- | 51.77 | -- | 20.67 | -- | 9.09 | -- | 0.00006 | -- | 21.13 | -- | -34.29 | -- | -- | -- |
| Jinyao Pharmaceutical Co Ltd | 3.66bn | 107.59m | 3.82bn | 2.68k | 35.46 | 1.26 | -- | 1.04 | 0.0984 | 0.0984 | 3.35 | 2.76 | 0.5738 | 2.28 | 9.37 | 1,365,219.00 | 2.33 | 1.91 | 4.17 | 3.40 | 42.61 | 46.33 | 4.06 | 3.31 | 0.7584 | 27.18 | 0.2064 | 44.40 | 2.55 | 9.28 | 230.60 | -4.22 | -9.58 | 9.21 |
| Zhejiang Starry Pharmaceutical Co Ltd | 2.27bn | 46.95m | 3.93bn | 1.85k | 65.57 | 1.74 | -- | 1.73 | 0.1368 | 0.1368 | 6.63 | 5.15 | 0.4179 | 1.98 | 5.09 | 1,231,642.00 | 0.8789 | 3.30 | 1.80 | 5.97 | 23.86 | 32.35 | 2.10 | 8.21 | 0.4121 | 1.44 | 0.6405 | 53.08 | 3.04 | 19.78 | 158.32 | -13.94 | 10.39 | -- |
| Shanghai Hile Bio-Technology Co Ltd | 239.79m | 44.92m | 3.99bn | 295.00 | 90.58 | 3.19 | -- | 16.63 | 0.0669 | 0.0669 | 0.3664 | 1.90 | 0.154 | 1.06 | 2.40 | 812,857.50 | 2.06 | 1.73 | 2.56 | 2.47 | 45.19 | 50.44 | 13.37 | 10.37 | 1.16 | -- | 0.0562 | 23.89 | -19.76 | -1.11 | -48.30 | 24.17 | -41.32 | 23.47 |
| Yabao Pharmaceutical Group Co Ltd | 2.88bn | 204.43m | 4.02bn | 4.14k | 20.26 | 1.38 | -- | 1.39 | 0.2754 | 0.2754 | 3.81 | 4.05 | 0.7193 | 2.98 | 6.79 | 695,432.10 | 4.52 | 2.82 | 5.90 | 3.97 | 56.00 | 59.20 | 6.29 | 4.19 | 1.62 | 47.13 | 0.0675 | 43.74 | 7.05 | -0.0572 | 90.71 | -6.10 | 7.98 | -9.71 |
| Jiangsu Jibeier Pharmaceutical Co Ltd | 889.82m | 233.59m | 4.04bn | 1.45k | 16.54 | 1.99 | -- | 4.55 | 1.24 | 1.24 | 4.74 | 10.37 | 0.426 | 3.13 | 5.33 | 615,794.80 | 11.17 | 9.77 | 12.06 | 10.66 | 87.87 | 88.44 | 26.22 | 23.29 | 6.76 | -- | 0.005 | 30.68 | 31.49 | 12.16 | 41.65 | 17.79 | 112.78 | -- |
Data as of Jul 26 2024. Currency figures normalised to Zhejiang Starry Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
9.37%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Rongtong Fund Management Co., Ltd.as of 31 Dec 2023 | 11.92m | 3.48% |
| China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 5.67m | 1.66% |
| E Fund Management Co., Ltd.as of 31 Dec 2023 | 4.61m | 1.35% |
| Galaxy Asset Management Co., Ltd.as of 31 Dec 2023 | 2.39m | 0.70% |
| Gfund Management Co., Ltd.as of 31 Dec 2023 | 2.24m | 0.66% |
| Yinhua Fund Management Co., Ltd.as of 31 Dec 2023 | 1.88m | 0.55% |
| Tebon Fund Management Co. Ltd.as of 31 Dec 2023 | 1.09m | 0.32% |
| The Vanguard Group, Inc.as of 04 Jul 2024 | 924.68k | 0.27% |
| Essence Fund Co., Ltd.as of 31 Dec 2023 | 789.26k | 0.23% |
| China Post & Capital Fund Management Co., Ltd.as of 31 Dec 2023 | 541.40k | 0.16% |
More ▼
Data from 31 Dec 2023 - 30 Jun 2024Source: FactSet Research Systems Inc.
